Loading quotes...
Forecast
| Buy |
0 |
| Hold |
0 |
| Sell |
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Euroapi to mothball metamizole production in Frankfurt and cut workforce
Euroapi will mothball its production facility for the painkiller metamizole in Frankfurt-Höchst at the end of the year and reduce the number of employees on site from around 750 to under 700. The company is withdrawing from several active ingredients for price-competitiveness reasons and plans to stepwise exit 13 substances by 2027. Across Europe many active-ingredient productions have been shifted in favor of Asian suppliers, which is why France is providing state funds to modernize Euroapi sites. Policymakers and industry are now debating subsidy programs and procurement rules to strengthen supply security and local value creation in active-ingredient production. » More on faz.net
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 355.97M | - |
| Gross profit | 55.72M | - |
| Net profit | -141.29M | - |
| EBITDA | 83.77M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €77.16M |
Number of shares | 95.53M |
52-week high/low | €3.26 - €0.77 |
| Dividends | No |
Beta | 0.98 |
P/E ratio | -0.21 |
PEG ratio | 0.00 |
P/B ratio | 0.10 |
P/S ratio | 0.09 |
Company profile
Euroapi SA develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. The company was incorporated in 2021 and is based in Paris, France.
| Name | EUROAPI |
| CEO | David Seignolle |
| Headquarters | Paris,
if France |
| Website | |
| IPO | 05/06/2022 |
| Employees | 3,133 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | EAPI.PA |
Pnk | EAPIF |
Frankfurt | 940.F |
Düsseldorf | 940.DU |
London | 0EAP.L |
Paris | EAPI.PA |
München | 940.MU |